Brief: Regenxbio Q2 Operating Expenses USD 78.756 Million
06/08/2026 12:06
BRIEF-Regenxbio Q2 Operating Expenses USD 78.756 Million Aug 06 (Reuters) - Regenxbio Q2 license & royalty revenue USD 103.841 million.
- Q2 net income USD 22.709 million
Recent news on REGENXBIO
See all newsBrief: Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
Regenxbio climbs as new director buys nearly $1 million of stock
Brief: Regenxbio Strengthens Board Of Directors With Appointment Of Greg Ciongoli
U.S. STOCKS ON THE MOVE-Strategy, Ecovyst, Azenta
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics